Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia

BMC Hematology

Volumn 15, Issue 1, 2015, Pages

  Assefa, Muluken ^a,b   Abegaz, Woldaregay Erku ^b   Shewamare, Aster ^c   Medhin, Girmay ^b   Belay, Mulugeta ^b  

^a Nationalities and Peoples' Regional Health Bureau   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c Zewditu Memorial Hospital   (Ethiopia)

Author keywords

Anemia; Ethiopia; HAART; HIV

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANEMIA; ARTICLE; BLOOD CELL COUNT; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; ETHIOPIA; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTION; PNEUMONIA; PREVALENCE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TOXOPLASMOSIS; TUBERCULOSIS; YOUNG ADULT;

EID: 85011053148     PISSN: None     EISSN: 20521839     Source Type: Journal    
DOI: 10.1186/s12878-015-0024-6     Document Type: Article

References (34)

1. Owiredu WK, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci. 2011;11(1):2-15.
2. Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R. Profile of hematological abnormalities of Indian HIV infected individuals. BMC Blood Disord. 2009;9:5.
3. Dhurve SA, Dhurve AS. Bone marrow abnormalities in HIV disease. Mediterr J Hematol Infect Dis. 2013;5(1):e2013033.
4. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):27S-43.
5. Re MC, Zauli G, Furlini G, Giovannini M, La Placa M. HIV-1 infection and hematologic picture. Microbiologica. 1991;14(2):165-76.
6. Bain BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Curr Opin Hematol. 1999;6(2):89-93.
7. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Rev. 2002;4(1):13-20.
8. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91(1):301-8.
9. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10(5):615-24.
10. Forna F, Moore D, Mermin J, Brooks JT, Were W, Buchacz K, et al. Hematologic changes associated with Zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda. J Int Assoc Physicians AIDS Care. 2009;8(2):128-38.
11. Mocroft A, Kirk O, Barton SE, DietrichM, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13(8):943-50.
12. Adias TC, Uko E, Erhabor O. Anaemia in human immunodeficiency virus infection: a review. Niger J Med. 2006;15(3):203-6.
13. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin Hematol. 2000;37(4 Suppl 6):18-23.
14. CSA. Ethiopian demographic and health survey 2011. Maryland, USA: ICF Internationa; 2012.
15. Ferede G, Wondimeneh Y. Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital. Northwest Ethiopia BMC Hematol. 2013;13(1):8.
16. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999;6(3):410-14.
17. MOH. Guideline for pediatric HIV/AIDS care and treatment in Ethiopia. Addis Ababa: MOH; 2007.
18. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(4):315-19.
19. Kyeyune R, Saathoff E, Ezeamama AE, Loscher T, Fawzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014;14:496.
20. Gedefaw L, Yemane T, Sahlemariam Z, Yilma D. Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south west Ethiopia: a comparative study. PLoS One. 2013;8(8):e72202.
21. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010;14(12):e1088-92.
22. Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M. Risk factors and correlates for anemia in HIV treatment-naive infected patients: a cross-sectional analytical study. BMC Res Notes. 2010;3:230.
23. Denue BA, Kida IM, Hammagabdo A, Dayar A, Sahabi MA. Prevalence of anemia and immunological markers in HIV-infected patients on highly Active antiretroviral therapy in Northeastern Nigeria. Infect Dis. 2013;6:25-33.
24. Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr. 2005;40(1):65-9.
25. Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematol Am Soc Hematol Educ Program. 2013;2013:377-81.
26. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses. 2005;21(3):200-6.
27. Omoregie R, Omokaro EU, Palmer O, Ogefere HO, Egbeobauwaye A, Adeghe JE, et al. Prevalence of anaemia among HIV-infected patients in Benin City. Nigeria Tanzan J Health Res. 2009;11(1):1-4.
28. Wills TS, Nadler JP, Somboonwit C, Vincent A, Leitz G, Marino K, et al. Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read. 2004;14(6):305-10. 313-305.
29. Vanasse GJ, Berliner N. Anemia in elderly patients: an emerging problem for the 21st century. Hematology Am Soc Hematol Educ Program. 2010:271-275
30. Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood. 1989;74(5):1455-63.
31. Lee SW, Kang YA, Yoon YS, Um SW, Lee SM, Yoo CG, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006;21(6):1028-32.
32. Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc. 2010;13:42.
33. Renner LA, Dicko F, Koueta F, Malateste K, Gueye RD, Aka E, et al. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA paediatric west African database to evaluate AIDS. Int AIDS Soc. 2013;16:18024.
34. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-60.